Juno stock spikes after cancer drug trial shows 91 percent remission rate
June 01, 2015 at 16:23 PM EDT
Seattle biotech Juno Therapeutics is continuing on its course of successful clinical trials for its innovative new cancer treatments, and that's great for business...